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Recent developments in paediatric gastrointestinal surgery have focused on minimally invasive surgery, the 
accumulation of high quality clinical evidence, and scientific research. The benefits of minimally invasive surgery for 
common disorders like appendicitis and hypertrophic pyloric stenosis are all supported by good clinical evidence. 
Although minimally invasive surgery has been extended to neonatal surgery, it is difficult to establish its role for 
neonatal disorders such as oesophageal atresia and biliary atresia through clinical trials because of the rarity of these 
disorders. Advances in treatments for biliary atresia and necrotising enterocolitis have been achieved through 
specialisation, multidisciplinary management, and multicentre collaboration in research; similarly robust clinical 
evidence for other rare gastrointestinal disorders is needed. As more neonates with gastrointestinal diseases survive 
into adulthood, their long-term sequelae will also need evidence-based multidisciplinary care. Identifying cures for 
long-term problems of a complex developmental anomaly such as Hirschsprung’s disease will rely on unravelling its 
pathogenesis through genetics and the development of iPSC-based therapy. 
 
Introduction 
Paediatric gastrointestinal surgery is used for a wide 
range of disorders that can be broadly classified into the 
common childhood diseases encountered on a daily 
basis and the rare developmental malformations with 
long-term consequences. In this Series paper, we review 
recent advances and remaining challenges in the 
management of six disorders. In the most common 
paediatric gastrointestinal disorders such as appendicitis 
and hypertrophic pyloric stenosis, good clinical evidence 
has confirmed the benefits of minimally invasive surgery. 
In the more complex neonatal gastrointestinal disorders 
such as oesophageal atresia and biliary atresia, the 
advantages of minimally invasive surgery have yet to be 
determined, but their management by multidisciplinary 
teams has improved primary outcomes, including 
survival. Patients with developmental defects often have 
long-term functional sequelae that cannot be corrected 
by surgery alone, leaving them with lifelong medical 
burdens that need the services of a diverse team of adult 
health-care professionals. 
Robust, evidence-based data to guide paediatric 
gastrointestinal surgical care is limited because of the 
rarity of most neonatal disorders, making multicentre 
collaboration necessary if strategic advances are to be 
made. Major advances in quality of care will likely rely on 
subspecialisation within the field. The benefit of 
specialisation is best illustrated in the case of biliary 
atresia, where the concentration of care in high-volume 
centres improves outcomes and allows the accumulation 
of evidence through combining multicentre data and 
randomised controlled trials. The benefit of multicentre 
studies is also well illustrated by some recent advances in 
treatment of necrotising enterocolitis, but many more of 
such studies are needed to fill the large gaps in highquality 
clinical evidence. Hirschsprung’s disease 
(congenital intestinal aganglionosis) is an example of a 
disease that cannot be cured by simple surgical correction 
because the physiological dysfunction persists; here the 
relevance of genetics and stem-cell therapies to 
supplement surgery is explored through multidisciplinary 
research in an attempt to find a cure. 
 
Advances in minimally invasive surgery 
Appendicitis 
Appendicitis is a common surgical emergency in 
children. Unlike adults, young children have immature 
immunological defence and might not be able to explain 
the symptoms, hence increasing the likelihood of 
perforation and therefore morbidity. Although some 
clinical scoring systems have been developed to improve 
the diagnostic accuracy in up to 80–90% of cases, their 
predictive value is still debatable, particularly in certain 
subpopulations.1 In adults, the problem of diagnostic 
uncertainty has led to the use of CT, which is very 
sensitive and specific—lowering the normal appendicectomy 
rate to 6%—and could reveal other important 
pathology, although the latter is of less concern in 
children.2 Although protocols for low-dose and limited 
CT scan protocols exist, this investigation has a less 
important role in the management of children because of 
the risks of radiation exposure.3 Ultrasonography is a 
better diagnostic tool where experience exists.4 
Appendicectomy has always been the standard treatment 
for appendicitis, and recently this has been predominantly 
done laparoscopically after the results of a systematic 
analysis5 showed its superiority over open operation in 
reducing wound infection and length of stay in hospital. 
Initial non-operative management is an acceptable option 
for children with complicated disease, especially those 
who present with an abscess or palpable mass. Nonoperative 
management usually involves a period of 
intravenous broad-spectrum antibiotics with or without 
abscess drainage, followed by continued antibiotics after 
discharge and a scheduled appendectomy in 6–8 weeks. 
Findings from a meta-analysis6 of complicated appendicitis 
in children and adults showed a reduction in complications 
and re-operation rates using non-operative management. 
Although results of a randomised controlled trial7 showed 
that more than three-quarters of children can avoid 
interval appendicectomy after successful non-operative 
management of an appendix mass, the risk factors for 
failure of non-operative management are yet to be fully 
determined. 
The application of non-operative management has also 
been extended to uncomplicated cases, with good 
outcomes from a randomised controlled trial in paediatric 
patients.8 Unlike for the complicated cases, antibiotic 
therapy is intended to be the definitive treatment for 
uncomplicated cases, with no interval appendicectomy 
scheduled. The questions remaining are, what percentage 
of patients will have recurrent appendicitis, and is 
this rate low enough to justify non-operative management 
as the primary treatment? In a meta-analysis9 of 
non-operative management for uncomplicated appendicitis, 
the overall failure rate was about 20%, and these 
data will serve as a baseline for several ongoing multicentre 
randomised trials. 
Hypertrophic pyloric stenosis 
Although appendicitis is the most common gastrointestinal 
disorder in children, hypertrophic pyloric 
stenosis is the most common disorder in infants that 
needs surgery (at a rate 0・2%). Hypertrophic pyloric 
stenosis is an obstructive idiopathic hypertrophy of the 
pyloric muscle and typically occurs at 1 month, and rarely 
later than 3 months of age, and with a clear male 
preponderance. In several studies, the first-born child 
has been shown to have the greatest risk.10 In other 
studies, an increased risk has been associated with 
caesarean delivery, bottle-feeding, and low gestational 
age at birth.10–12 The presentation is non-bilious projectile 
vomiting in an infant who otherwise appears well and 
shows hunger after vomiting. Historically, diagnosis was 
confirmed by a palpable olive-shaped mass in the 
epigastrium. Ultrasound is accurate, efficient, and 
inexpensive and has thus become the current standard 
diagnostic modality. 
The protracted vomiting leads to acid loss and 
dehydration with renal compensation creating hypochloraemic, 
hypokalaemic metabolic alkalosis with paradoxical 
aciduria. The electrolyte imbalance might represent 
a medical emergency, but never a surgical emergency; 
rehydration is therefore done until electrolyte correction 
and evidence of normal tissue perfusion with brisk capillary 
refill and moist mucous membranes. The operation rarely 
occurs on the day of admission to allow for rehydration.13 
The curative procedure is division of the circular and 
longitudinal muscle layers of the pylorus, leaving the 
mucosa and submucosa intact. The procedure has 
traditionally been performed with an upper abdominal 
incision but is now increasingly done by laparoscopy 
(figure 1), with support from evidence from several 
randomised trials.14 In long-term follow-up, the appearance 
of the abdomen of patients who had laparoscopic 
pyloromyotomy is indistinguishable from those who have 
no operation.15 Circumumbilical incision but open surgery 
is alternative approach with the same cosmetic benefit. 
Irrespective of access, the prognosis is excellent, with 
most patients resuming feeds and going home in 1–2 days 
after the operation. 
The two complications of pyloromyotomy are mucosal 
perforation or incomplete myotomy. Traditional teaching 
was that perforations were more likely to occur from 
extending the myotomy too distal, whereas incomplete 
myotomies occur from not going proximal enough. 
Mucosal perforation occurs in about 0・5% of cases, and 
incomplete myotomy also usually occurs in less than 1% of 
cases.16 However, in one study,17 no incomplete myotomies 
occured when the myotomy was at least 2 cm in length. 
Post-operatively, traditional reintroduction of feeds 
followed protocols that used a period of stomach rest 
followed by incremental increases in volume and 
concentration.18 Randomised data show that feeds can be 
safely reintroduced at goal levels.19 Feeds on demand are 
therefore becoming the preferred and more efficient 
means of post-operative feeding. 
Figure 1: Laparoscopic pyloromyotomy 
 
Challenges for evidence-based surgery 
Oesophageal atresia 
By contrast with common disorders in children that 
need surgery, neonatal gastrointestinal disorders are 
rare, complex, poorly understood, and sometimes lifethreatening. 
These patients need multidisciplinary 
management and frequently have long-term problems, 
despite initial life-saving surgery. Although surgical 
innovations to improve outcomes exist, the difficulty is 
to accumulate high-quality evidence to guide advances 
for these rare and heterogeneous diseases. 
Oesophageal atresia with or without distal tracheooesophageal 
fistula is a congenital anomaly that affects 
1/4000 newborn babies and represents the quintessence 
of neonatal gastrointestinal surgery. About 85% of 
patients with oesophageal atresia have a proximal blindending 
oesophagus just beyond the thoracic inlet and a 
distal oesophagus entering the trachea at or above the 
carina.20 Other types include pure atresia (oesophageal 
atresia, no tracheo-oesophageal fistula; 7%), which is 
characterised by a long gap between the oesophageal 
ends, H-type tracheo-oesophageal fistula with no atresia 
(5%), double tracheo-oesophageal fistula with oesophageal 
atresia, and proximal tracheo-oesophageal 
fistula with oesophageal atresia. Oesophageal atresia 
was once a lethal disorder, but survival have markedly 
improved to more than 90% because of advances 
in multidisciplinary perioperative care in neonatal 
surgical centres and innovative surgical strategies for 
different anomalies. 
Oesophageal atresia is associated with other congenital 
anomalies, often as part of the VACTERL complex: 
Vertebral (24%), Anorectal (14%), Cardiac (32%), TracheooEsophageal 
fistula (95%), Renal (17%), Limb/ 
skeletal (16%), and others (11%).21 Associated with a 
prenatal history of polyhydramnios, oesophageal atresia 
can be diagnosed by prenatal ultrasound with a sensitivity 
of only around 50%, although specificity is high, especially 
for pure oesophageal atresia.22 However, prenatal 
diagnosis does not affect outcome. Diagnosis at birth is 
readily evident in children who are unable to swallow or 
when an orogastric tube cannot be inserted. X-ray will 
show a radio-opaque orogastric tube coiled up at the 
thoracic inlet and can reveal associated skeletal anomalies; 
pure oesophageal atresia shows the additional feature of a 
gasless abdomen. 
About 60% of surgeons will use bronchoscopy to 
identify the location of the fistula and rule out a fistula 
from the proximal pouch.20,23 The operation can then be 
either open or thoracoscopic (figure 2). The first thoracoscopic 
repair was reported in 1999.24 In a survey of 
surgeons interested in minimally invasive surgery, half 
of the respondents use the thoracoscopic approach.23 In a 
study of 11 US medical centres, only 8% of the cases were 
treated thoracoscopically.20 Randomised trials are scarce, 
but in a meta-analysis,25 outcomes after open surgery 
versus thoracoscopic repair were comparable; thoracoscopy 
took the longest time, but was associated with the 
shortest time to extubation, feeding, and discharge. The 
long operating time could be of concern in view of results 
from a pilot randomised trial that revealed high arterial 
CO₂ and low pH during thoracoscopic repair, increasing 
the potential risk for brain damage due to hypoxia.26 
Perioperative management varies widely and includes 
the use of post-operative paralysis, antibiotics, acid 
suppression, and many other parameters.20,23,27 As an 
example, a multicentre series showed no benefit to 
antibiotics or acid suppression; however, some surgeons 
use protracted antibiotics and recommend acid 
suppression for life.20,28 Traditional practice has also 
included trans-anastomotic stent placement, but this 
procedure is now associated with harm.28 The variation in 
care is an opportunity for the paediatric surgical community 
to design studies of new methods to improve 
care for these infants. 
The most challenging cases of oesophageal atresia are 
those with a long gap, defined as at least 3 cm or 
three vertebral bodies between the two ends of the 
oesophagus, which is usually associated with pure 
oesophageal atresia. In a recent position paper, the 
Working Group on long-gap oesophageal atresia29 called 
for a new definition to include only pure atresia and for 
these cases be referred to high-volume centres. The 
two strategies for oesophageal preservation are 
anastomosis under tension and delayed anastomosis with 
Figure 2: Thoracoscopic repair of oesophageal atresia (oesophageal atresia) with distal trachea-oesophageal 
fistula 
(A) Thoracoscopic view (patient in prone position) showing tracheo-oesophageal fistula occlusion (Haemoclip 
used here, but ligation or suturing is preferred by some surgeons) and division; the diagram shows the distal 
tracheo-oesophageal fistula inserting into the back of the trachea just above the carina and blind proximal 
oesophageal pouch at the thoracic inlet (outside this thoracoscopic image). (B) Completed oesophageal 
anastomosis; the diagram shows anastomosis of proximal and distal oesophageal segments. 
A 
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staged operations to stretch the oesophagus by placing 
tension on the ends using traction sutures.27 Although 
uncommon, these cases can also be approached 
thoracoscopically. The alternative to oesophageal preservation 
is replacement, with gastric, colonic, or jejunal 
replacement. The technically difficult method of jejunal 
interposition has been advocated.30 The limited comparative 
data does not delineate a superior option.31 The 
low quality of evidence on this topic will probably not 
change in the near future, given the rarity of the disorder. 
The best results are likely to be attained by surgeons who 
gain experience with one approach and build solid 
experience. 
The main early postoperative complication is leakage of 
anastomosis, occurring in 20% of cases.20 Most of these 
cases can be managed conservatively with drainage and 
usually heal in 1–2 weeks. Strictures, defined as the need 
for oesophageal dilatation, are the most common 
complication and occur in about 40% of cases.20 Most 
cases of stricture can be managed with dilations alone. 
Vocal cord paralysis, presumably from recurrent laryngeal 
nerve injury, occurs in about 5% of routine cases32 but can 
occur in more than 20% of patients with H-type fistulas.20 
Recurrent fistulas occur in about 5% of cases. A variety of 
techniques for endoscopically obliterating recurrent 
fistulas have been described,33 but surgical repair has the 
highest success rate and requires fewest treatments.34 
Even after successful surgery, patients have severely 
impaired oesophageal motility, predisposing to gastrooesophageal 
reflux and associated complications.35 
Intestinal metaplasia of the oesophageal mucosa occurs 
in 6–11% of young adults after oesophageal atresia 
repair.35,36 The prevalence of metaplastic epithelial 
alterations of the oesophagus increases with age, whereas 
eight cases of oesophageal cancer have been reported in 
patients with oesophageal atresia younger than 50 years.37 
International multicentre studies are needed to define 
the risk of intestinal metaplasia and oesophageal cancer 
so as to guide evidence-based endoscopic follow-up 
protocols for patients after transition to adult care. 
 
Biliary atresia 
Despite being the most common cause of obstructive 
jaundice in infancy, biliary atresia is a very rare neonatal 
gastrointestinal disorder for which high-quality 
clinical 
evidence is limited to a few studies from highly 
specialised centres. Biliary atresia is characterised by the 
obliteration of all or part of the extrahepatic bile duct, 
sometimes with absent parts. The incidence of biliary 
atresia varies between ethnic groups, being more 
common in Asian populations (about 1/5000 Asians vs 
1/18000 Caucasians).38 Biliary atresia is probably a final 
common pathway of a number of possible pathogenic 
mechanisms that could include genetic,39 inflammatory, 
environmental, and developmental abnormalities 
(figure 3). One hypothesis suggests that an inflammatory 
cholangiopathy is triggered perinatally by viral exposure 
acting in a genetically predisposed patient.40 Although 
biliary atresia appears to be an isolated disease in most 
cases, in about 10–20% of western series, it is associated 
with other visceral anomalies such as polysplenia, situs 
inversus, and a pre-duodenal portal vein (biliary atresia 
splenic malformation syndrome).41 The possible association 
of a cytomegalovirus has been studied for many 
years, and cytomegalovirus-related biliary atresia could 
be a different form of biliary atresia with worse prognosis. 
42 Further work is needed before a definitive 
conclusion can be made. 
Biliary atresia should be managed by experienced 
surgeons in a specialised centre. Findings from national 
studies in England and Wales, Finland, and the 
Netherlands have shown that centralising resources 
improves the outcomes for those with biliary atresia.43–45 
Excision of the fibrous cord at a precise level at the porta 
Figure 3: Schematic illustration of proposed aetiology of biliary atresia 
Dotted lines indicate influence or contributory factors. Thin arrows indicate various inter-relations. Thick arrows indicate principal types of biliary atresia 
(isolated vs 
developmental). 
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Clinical features 
and portoenterostomy introduced by Kasai is regarded as 
the best hope for salvaging the native liver and restoring 
bile flow, although the outcome remains variable and 
unpredictable. Clearance of jaundice can be achieved in 
60–70% of infants, with a 5 year native liver survival rate 
of around 50%, although even those children cannot be 
regarded as cured.43–45 A direct correlation between the 
age at operation and the outcome can be difficult to 
discern even in large series, probably reflecting the 
variable underlying pathology.46,47 It remains axiomatic 
that the fibrotic process within the liver is time-critical 
and ultimately irreversible. 
The outcomes of a recent systematic review48 of the 
laparoscopic technique of portoenterostomy, suggests 
inferiority compared with conventional surgery. Results 
of a small randomised study have since shown no 
advantage of the technically more challenging laparoscopic 
technique,49 and in another small comparative 
study,50 patients who had laparoscopic portoenterostomy 
had higher jaundice clearance but poorer biomarker 
values than patients who had open portoenterostomy, 
although these differences were statistically nonsignificant. 
The debate of open versus laparoscopic 
portoenterostomy is unlikely to be resolved without large 
randomised controlled trials involving multiple centres 
with relevant expertise and high volumes. 
Adjuvant treatments to improve the success of surgery 
have been studied extensively, and steroids are one of the 
most popular drugs available. The effect of steroids on 
the outcomes of biliary atresia has been assessed in three 
meta-analyses, the most recent51 of which showed a 
higher jaundice clearance rate in patients given a high-tomoderate 
dose of steroid, especially those operated on 
before day 70 of life. The proposed explanation is that 
steroids work better on the early inflammatory stage of 
disease when fibrosis is less prevalent. 
Cholangitis has long been known as a post-operative risk 
factor that affects the outcome of biliary atresia. Recurrent 
cholangitis in particular is an important prognostic marker 
for predicting disease progression according to the results 
of one multivariate analysis.52 Treating post-operative 
cholangitis aggressively is therefore essential to prevent 
disease progression. Although some surgeons have 
advocated prophylactic use of antibiotics, the evidence for 
this is scanty. Prolonged antibiotics might be justified when 
cholangitis becomes intractable. Home administration of 
intravenous antibiotics is a practical approach for those 
patients needing long-term treatment with a reduction in 
hospital stay.53 
Despite a Kasai portoenterostomy, about 30–40% of 
patients will develop end-stage liver disease. The native 
liver survival rate decreases with time, with the 5 year, 
10 year, and 20 year survival rates estimated in one study 
to be 63%, 54%, and 44%, respectively.54 These long-term 
survivors with native livers slowly develop liver cirrhosis 
and its sequelae. A multicentre consortium reported 
high incidences of cholangitis (17%) and fractures (95%) 
and suboptimal health-related quality of life (47%) on 
long-term follow-up.55 Conversely, normal school education 
was reported in most survivors with a native 
liver (88%).56 Hence, lifelong postoperative care and 
surveillance should be continued, preferably in a 
dedicated centre. 
For patients who deteriorate after Kasai portoenterostomy, 
liver transplantation is the only viable 
treatment option in most patients.57 The overall longterm 
success rate of liver transplantation for patients 
with biliary atresia is 74–86%, and survivors can enjoy 
normal health-related quality of life despite the need for 
life-long immunosuppression.58–60 However, access to 
donor organs is still a limitation in most places. Deceased 
donors are still the standard in Europe and North America, 
whereas living donor programmes61–62 are paramount in 
China, Japan, and South Korea, essentially for cultural 
reasons. 
Necrotising enterocolitis 
Although the diagnosis and surgery of oesophageal 
atresia and biliary atresia is quite standardised, this is not 
true of all diseases in newborn children. Necrotising 
enterocolitis, the most common surgical emergency in 
premature newborn babies, is an acquired inflammatory 
disorder affecting the gastrointestinal tract. Despite 
decades of research, the aetiology of necrotising enterocolitis 
remains elusive, and optimal treatment and 
preventive strategies are still not well defined. In the past 
few years, however, data from several clinical trials and 
population studies on aetiological factors have emerged. 
Of the many theories on the development of necrotising 
enterocolitis, an interesting possibility is the abnormal 
colonisation of the preterm infant’s gastrointestinal tract 
with pathogenic Gram-negative organisms. Findings 
from prospective serial stool sample analysis by 16S rRNA 
sequencing63 showed that, whereas the normal premature 
infant gut undergoes bacterial colonisation in a systematic 
fashion (from Bacilli to Gammaproteobacteria to 
Clostridia), necrotising enterocolitis is preceded by a 
relative abundance of Gammaproteobacteria (facultative 
Gram-negative bacilli) and a paucity of strict anaerobes.64,65 
This suggests that identification and modulation of the 
microbiome could allow for early diagnosis and treatment 
of necrotising enterocolitis. 
A generalised Gammaproteobacteria dysbiosis alone, 
however, does not fully explain the disease. With new 
technologies, the potential causative strains of bacteria can 
be identified and insight can be gained into the role of the 
host–bacterial interaction in necrotising enterocolitis 
development. Results from a metagenomic sequencing 
study66 has implicated colonisation with specific 
Escherichia coli subtypes as a risk factor for developing 
necrotising enterocolitis. The Gram-negative bacterial cell 
wall component lipopolysaccharide is the ligand for Tolllike 
receptor 4 (TLR-4). Compared with infants born to 
term, the enterocytes of preterm infants show excessive 
TLR-4 signalling in response to lipopolysaccharide, and 
TLR-4 could be part of a signalling pathway through which 
pathogenic bacteria induce necrotising enterocolitis. Thus, 
TLR-4 is a promising target for therapeutic intervention in 
necrotising enterocolitis,67 and clinical trials are being 
developed.68 
In view of the importance of the microbiota in 
stimulating the inflammatory cascade that leads to 
necrotising enterocolitis, numerous bacteria-derived and 
host-derived biomarkers have been investigated. Faecal 
calprotectin,69 urine alanine,70 and urine intestinal fatty 
acid-binding protein71 are examples of promising biomarkers; 
however, they have yet to be validated. Biomarkers 
could become the best opportunity to achieve 
early diagnosis, which would be a paradigm shift in 
necrotising enterocolitis. 
Prevention of necrotising enterocolitisis is ideal. 
Human breast milk decreases the risk of necrotising 
enterocolitis, presumably by reducing colonisation with 
pathogenic bacteria, while promoting the growth of 
commensal organisms and blunting the inflammatory 
response. Putative protective factors in breast milk 
include secretory IgA, epidermal growth factor,72 and 
human milk oligosaccharides.73 These factors might exert 
their protective effects, in part, by modulating bacterial– 
epithelial interaction via TLR-4.66 However, necrotising 
enterocolitis can occur despite the use of breast milk, and 
no single component of human breast milk given as a 
formula additive can decrease the incidence of human 
necrotising enterocolitis. There may be additional, 
unknown components in breast milk, or perhaps it is the 
combination of factors that lead to its beneficial effects. 
Another preventive strategy is to modulate the microbiota 
using probiotics. Results of a Cochrane review74 showed 
that enteral probiotics significantly reduced the incidence 
of advanced necrotising enterocolitis and decreased 
mortality, with no reported systemic infections. In a more 
recent meta-analysis,75 probiotics were also found to 
decrease the risk of necrotising enterocolitis and death. 
Data from a randomised trial of 1315 preterm infants 
comparing Bifidobacterium breve and placebo showed no 
difference in the incidence of necrotising enterocolitis, 
sepsis, or death in either treatment group.76 The use of a 
new probiotic strain here might explain the negative 
finding. The concern for potential risk of bacteraemia, 
although unproven, has impeded universal acceptance of 
probiotics. This highlights the difficulty of studying 
necrotising enterocolitis, where thousands of patients 
must be enrolled to show a change in incidence. Since a 
myriad of organisms and doses could be tested in trials of 
probiotics, it is no surprise that the role of probiotics in 
necrotising enterocolitis prevention is still undefined. 
Overall, surgical intervention is still necessary in up to 
50% of necrotising enterocolitis cases for intestinal 
necrosis or perforation (figure 4).77 Findings from large, 
population-based studies in the UK and the USA show a 
substantial increase in mortality to at least 30% of 
operative necrotising enterocolitis cases.78,79 Peritoneal 
drainage, in lieu of laparotomy, has been used to minimise 
operative risk in critically ill, premature infants. Studies 
surrounding this concept are the best example of clinical 
trials guiding the treatment of necrotising enterocolitis. In 
a North American randomised controlled trial80 of 
117 patients weighing less than 1500 g with perforated 
necrotising enterocolitis from 15 centres, no difference 
was found in mortality, total parenteral nutrition 
dependence, or length of hospital stay in neonates treated 
with drain or laparotomy. In a European randomised 
controlled trial81 of 69 patients weighing less than 1000 g 
from 31 centres, although no difference was seen in 
outcomes (6 month survival was 51・4% with drain and 
63・6% with primary laparotomy; p=0・3), 74 % of patients 
who had peritoneal drainage needed rescue laparotomy, 
and thus laparotomy was superior. The long-term effects 
of either treatment were not examined. Results of the 
Neonatal Research Network prospective cohort study82 
suggest that long-term outcome (>18 months) might be 
better with laparotomy than with peritoneal drainage. 
Additional insight on this issue is anticipated from the 
ongoing Necrotizing Enterocolitis Surgery Trial 
(NCT01029353). These and other similar studies are 
crucial for improving the acute management of the 
disease, which has long-term implications for children 
living with short gut, dysmotility, and neurological 
sequelae as a result of necrotising enterocolitis. 
 
Surgery meets science: Hirschsprung’s disease 
Among the rare neonatal gastrointestinal disorders, 
Hirschsprung’s disease (congenital intestinal aganglionosis) 
exemplifies a developmental anomaly for which 
Figure 4: Plain abdominal X-ray of an infant with perforated necrotising 
enterocolitis showing pneumoperitoneum 
clinical trials alone are unlikely to alter the unsatisfactory 
outcome. Current operative techniques are inherently 
imperfect: they relieve neonatal intestinal obstruction but 
are not able to eradicate lifelong sequelae related to bowel 
dysfunction, because to preserve faecal continence they 
invariably leave behind the aganglionic internal sphincter. 
Here the surgery-meets-science scenario is being used in 
an attempt to find a cure through multidisciplinary 
research.83 
Defective cranial–caudal migration of vagal neural-crest 
cells along the intestine during early embryonic 
development is known to result in Hirschsprung’s disease.92 
Despite an incidence of only 1/5000 births, Hirschsprung’s 
disease is the most common congenital enteric neuropathy. 
Disease severity varies between patients: the aganglionosis 
is limited to the rectum and the rectosigmoid colon in 80% 
of cases, but extends more proximally to various lengths of 
the intestine in the remaining cases. Delayed passage of 
meconium, constipation, bilious vomiting, and abdominal 
distension are clinical hallmarks of Hirschsprung’s disease. 
Hirschsprung’s-associated enterocolitis, typically manifested 
by fever, diarrhoea, and increased abdominal 
distension, is a life-threatening complication in 6–60% of 
patients that requires early decompression (rectal 
washouts) and antibiotics.84 Although the exact cause of 
Hirschsprung’s-associated enterocolitis is unknown, 
research findings suggests that changes in the intestinal 
barrier, abnormal intestinal mucosal immunity, and 
dysbiosis of the gut flora could contribute to its 
development. 
The gold standard of diagnosis for Hirschsprung’s 
disease is rectal biopsy showing an absence of ganglia. 
Diagnostic accuracy can be improved with ancillary 
tests such as acetylcholinesterase histochemistry (showing 
thickened nerve fibres) and the more reliable 
calretinin immunohistochemistry (showing an absence 
of calretinin immunoreactivity).85 
After diagnosis, the traditional treatment was temporary 
bowel decompression with a stoma formation, 
followed 
by an open pull-through operation at a later age and 
closure of the stoma. Transanal rectosigmoidectomy with 
or without laparoscopic assistance has become the 
surgical standard for short-segment Hirschsprung’s 
disease after its introduction in the late 1990s.86 Singlestage 
pull-through has been increasingly done in neonates 
with Hirschsprung’s disease without evidence from 
prospective comparative trials;87 findings from a 
retrospective, multi-institutional cohort88 suggest that 
although single-stage pull-through has some clinical 
advantages (reduced rates of wound infection, postoperative 
enterocolitis, and adhesive bowel obstruction 
and reduced duration of hospital stay), multistage pullthrough 
might be necessary for the subgroup of severely 
ill infants with Hirschsprung’s disease. 
Surgery is effective in the short term, but functional 
issues remain. Collective data from earlier studies 
suggested that bowel dysfunction, including constipation, 
soiling, and Hirschsprung’s-associated enterocolitis, 
persisted in 14% of patients who had pull-through.89 
Assessment of long-term functional outcomes in patients 
reaching adulthood has improved recently.90,91 According 
to population-based and multicentre follow-up studies,90,91 
75% of the patients are socially continent in cross-section, 
but imperfections in faecal control diminish with age, 
allowing quality of life comparable to controls. However, 
the emotional and sexual deficiencies that might prevail 
in adulthood and lead to social limitations should be 
investigated further.90 High-quality clinical evidence 
could guide empirical treatment and improve outcomes, 
but bowel resection alone cannot cure an abnormal 
enteric nervous system. In the past decade, developmental 
biologists, geneticists, stem-cell biologists, pathologists, 
gastroenterologists, and surgeons have been 
collaborating in multidisciplinary research to better 
understand the disease mechanisms of Hirschsprung’s 
disease and design new management strategies involving 
precision and regenerative medicine. 
The enteric nervous system is complex and contains as 
many neurons as the spinal cord. Until recently, 
neither the cause of the defect nor the heterogeneity 
of Hirschsprung’s disease were well understood. 
Hirschsprung’s disease is now understood to be an oligogenic 
disorder with variable clinical subtypes. The rare 
subtype with long-segment aganglionosis or familial 
Hirschsprung’s disease (4–8%) and associated syndromes 
(Down syndrome, Shah–Waardenburg syndrome, 
Haddad syndrome, Mowat–Wilson syndrome) have 
dominant or recessive inheritance with incomplete 
penetrance. The common, sporadic short-segment subtype 
of Hirschsprung’s disease follows a complex non- 
Mendelian inheritance pattern.93,94 The most important 
gene associated with Hirschsprung’s disease is RET, 
which encodes the RET receptor tyrosine kinase protein, a 
cell-surface signal transducer. Deleterious coding mutations 
in RET are found in 50% of familial cases but only 
in 20% of the more common sporadic cases; other 
Hirschsprung’s disease genes have been identified, but 
these account for only an additional 7% of sporadic cases 
(figure 5).93 In most patients with sporadic Hirschsprung’s 
disease, the aetiology is complex and might involve several 
disease susceptibility factors, including non-coding 
(regulatory) mutations.94 Current technology allows the 
whole genome to be searched for genes involved in 
Hirschsprung’s disease; for example, the Neuregulin1 
gene(NRG1) was implicated in Hirschsprung’s disease in 
a genome-wide association study,95 and several more 
candidate genes are being identified by whole-exome 
sequencing.96 Genotype–phenotype correlations in large 
patient populations will provide the basis of precision 
medicine, which could allow treatment options to be 
tailored according to genetic classification of patient 
subtypes. 
Since the primary pathology of Hirschsprung’s disease 
is an absence of enteric ganglion cells, an attractive 
alternative to resection of aganglionic bowel tissue is cellreplacement 
therapy. General advances in stem-cell 
biology and breakthroughs in induced human pluripotent 
stem-cell (iPSC) research in particular (avoiding ethical 
and immunological obstacles), have raised hope of 
regenerative medicine as a treatment option for patients 
with Hirschsprung’s disease. The successful production 
of functional enteric neurons from human iPSCs has 
provided proof-of-concept evidence for this approach.97 
Human iPSCs have also been used to recapitulate 
Hirschsprung’s disease development under cell-culture 
conditions, allowing correction of Hirschsprung’s 
disease-associated mutations by genome editing and 
identifying possible drug targets for disease treatment.98 
As an alternative to a pure cell-based approach, human 
iPSC-derived tissue with a functional enteric nervous 
system can now be engineered for transplantation into 
patients with short bowel syndrome associated with 
ultra-long-segment Hirschsprung’s disease.99 These 
studies have prompted a multidisciplinary group of 30 
experts to conclude that although many obstacles remain 
to be overcome, clinical application of enteric neural 
stem cells and first-in-human trials for Hirschsprung’s 
disease is now a real prospect.100 
Discussion 
In the next 5–10 years, paediatric gastrointestinal 
surgeons should focus efforts on generating robust 
clinical evidence, which is particularly deficient in rare 
neonatal gastrointestinal disorders. The popularisation 
of minimally invasive surgery in the management of 
common childhood disorders exemplifies the importance 
of well designed randomised controlled trials in the 
justification of new treatment modalities. The outcome 
of such trials for non-operative treatment of appendicitis 
is now eagerly awaited (NCT02687464, NCT02271932, 
NCT02795793). As findings from several studies of 
biliary atresia and necrotising enterocolitis have shown, 
the patient volume needed to achieve high-quality clinical 
evidence for neonatal gastrointestinal disorders is 
achievable through specialisation and international 
research consortiums. The evidence for minimally 
invasive surgery in oesophageal atresia and biliary atresia 
is still scarce: the paediatric surgical community needs 
not only to show leadership in designing multicentre, 
randomised controlled trials to resolve these issues in an 
objective manner but also to set the best standards of 
paediatric surgical care. 
The results of novel microbiome studies in necrotising 
enterocolitis open up the possibility of prevention 
through early diagnosis with new biomarkers and by 
modifying microbiota–host interactions with relevant 
probiotics and early intervention by targeting the TLR-4 
signalling pathway; the latter represents pathophysiologybased 
management. The final clinical value of these 
translational achievements can only be confirmed with 
large, multicentre patient cohorts managed by 
multidisciplinary teams. The multidisciplinary teams 
will have the responsibilities of not only enhancing 
short-term results but also, more importantly, improving 
long-term outcomes, involving adult practitioners and 
specialists for transition care, and promoting follow-up 
studies beyond childhood. 
When available measures alone are insufficient to 
eradicate the long-term sequelae, as in the case of 
Hirschsprung’s disease, genetic studies and iPSC 
research have the potential to provide better treatment, 
either by enabling pathophysiology-based selection of 
patient subgroups for surgery, or, more radically, by 
providing iPSC-based therapy as an alternative or adjunct 
to existing surgery. 
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